- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tudor Investment Corp Boosts Stake in Evolent Health
Hedge fund increases holding in healthcare technology company by over 170%
Apr. 9, 2026 at 9:10am
Got story updates? Submit your updates here. ›
An extreme close-up of the complex financial infrastructure powering the healthcare industry's shift towards value-based care.Arlington TodayTudor Investment Corp ET AL, a prominent hedge fund, has significantly increased its stake in Evolent Health, Inc. (NYSE: EVH), a healthcare technology and services company. According to a recent SEC filing, the firm acquired an additional 438,095 shares of Evolent Health during the third quarter, bringing its total ownership to 689,262 shares worth approximately $5.83 million.
Why it matters
This investment move by Tudor Investment Corp, a respected institutional investor, suggests confidence in Evolent Health's growth potential and the firm's belief in the company's ability to navigate the evolving healthcare landscape. As Evolent Health partners with health systems, physician organizations, and health plans to design and operate value-based care programs, Tudor's increased stake signals that the hedge fund sees long-term value in the company's business model and technology platforms.
The details
Tudor Investment Corp ET AL's stake in Evolent Health now represents about 0.62% of the technology company's outstanding shares. The hedge fund's increased position comes as Evolent Health has faced some challenges, with its stock price declining from a 52-week high of $12.06 to around $2.57 per share. However, several equity research analysts have maintained buy ratings on the stock, citing the company's potential to help healthcare providers transition to value-based care arrangements.
- Tudor Investment Corp ET AL disclosed the increased stake in Evolent Health in a Q3 2026 SEC filing.
The players
Tudor Investment Corp ET AL
A prominent hedge fund that has increased its stake in Evolent Health by over 170% during the third quarter of 2026.
Evolent Health, Inc.
A healthcare technology and services company that partners with health systems, physician organizations, and health plans to design and operate value-based care programs.
What’s next
Investors will be closely watching Evolent Health's upcoming financial results and any further updates on the company's partnerships and growth initiatives as it continues to navigate the evolving healthcare landscape.
The takeaway
Tudor Investment Corp's significant increase in its stake in Evolent Health suggests that the hedge fund sees long-term value in the company's healthcare technology and services offerings, which could help healthcare providers transition to value-based care models.
Arlington top stories
Arlington events
Apr. 10, 2026
Safety Not GuaranteedApr. 11, 2026
Safety Not GuaranteedApr. 11, 2026
Safety Not Guaranteed



